nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ABCC2—Sulfasalazine—ankylosing spondylitis	0.18	0.191	CbGbCtD
Canagliflozin—ABCC2—Dexamethasone—ankylosing spondylitis	0.09	0.0955	CbGbCtD
Canagliflozin—ALB—Prednisone—ankylosing spondylitis	0.0899	0.0953	CbGbCtD
Canagliflozin—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0776	0.0823	CbGbCtD
Canagliflozin—ABCC2—Methotrexate—ankylosing spondylitis	0.0724	0.0767	CbGbCtD
Canagliflozin—ABCB1—Betamethasone—ankylosing spondylitis	0.0505	0.0535	CbGbCtD
Canagliflozin—ABCB1—Prednisolone—ankylosing spondylitis	0.0498	0.0528	CbGbCtD
Canagliflozin—ABCB1—Prednisone—ankylosing spondylitis	0.047	0.0499	CbGbCtD
Canagliflozin—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0465	0.0493	CbGbCtD
Canagliflozin—ALB—Methotrexate—ankylosing spondylitis	0.0451	0.0478	CbGbCtD
Canagliflozin—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0352	0.0374	CbGbCtD
Canagliflozin—CYP3A4—Betamethasone—ankylosing spondylitis	0.0302	0.0321	CbGbCtD
Canagliflozin—CYP3A4—Prednisolone—ankylosing spondylitis	0.0298	0.0316	CbGbCtD
Canagliflozin—ABCB1—Dexamethasone—ankylosing spondylitis	0.0294	0.0311	CbGbCtD
Canagliflozin—CYP3A4—Prednisone—ankylosing spondylitis	0.0282	0.0299	CbGbCtD
Canagliflozin—ABCB1—Methotrexate—ankylosing spondylitis	0.0236	0.025	CbGbCtD
Canagliflozin—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0176	0.0186	CbGbCtD
Canagliflozin—Blood potassium increased—Prednisone—ankylosing spondylitis	0.00194	0.0341	CcSEcCtD
Canagliflozin—Sunburn—Methotrexate—ankylosing spondylitis	0.00162	0.0285	CcSEcCtD
Canagliflozin—Multiple fractures—Methylprednisolone—ankylosing spondylitis	0.00127	0.0224	CcSEcCtD
Canagliflozin—Fracture—Methylprednisolone—ankylosing spondylitis	0.00127	0.0224	CcSEcCtD
Canagliflozin—Multiple fractures—Betamethasone—ankylosing spondylitis	0.00116	0.0204	CcSEcCtD
Canagliflozin—Fracture—Dexamethasone—ankylosing spondylitis	0.00116	0.0204	CcSEcCtD
Canagliflozin—Fracture—Betamethasone—ankylosing spondylitis	0.00116	0.0204	CcSEcCtD
Canagliflozin—Multiple fractures—Dexamethasone—ankylosing spondylitis	0.00116	0.0204	CcSEcCtD
Canagliflozin—Fracture—Prednisone—ankylosing spondylitis	0.00101	0.0177	CcSEcCtD
Canagliflozin—Multiple fractures—Prednisone—ankylosing spondylitis	0.00101	0.0177	CcSEcCtD
Canagliflozin—Rash erythematous—Dexamethasone—ankylosing spondylitis	0.000878	0.0154	CcSEcCtD
Canagliflozin—Rash erythematous—Betamethasone—ankylosing spondylitis	0.000878	0.0154	CcSEcCtD
Canagliflozin—Fracture—Methotrexate—ankylosing spondylitis	0.000842	0.0148	CcSEcCtD
Canagliflozin—Multiple fractures—Methotrexate—ankylosing spondylitis	0.000842	0.0148	CcSEcCtD
Canagliflozin—Diabetes mellitus—Prednisolone—ankylosing spondylitis	0.000673	0.0118	CcSEcCtD
Canagliflozin—Diabetes mellitus—Triamcinolone—ankylosing spondylitis	0.000619	0.0109	CcSEcCtD
Canagliflozin—Diabetes mellitus—Methylprednisolone—ankylosing spondylitis	0.000617	0.0109	CcSEcCtD
Canagliflozin—Diabetes mellitus—Betamethasone—ankylosing spondylitis	0.000561	0.00987	CcSEcCtD
Canagliflozin—Diabetes mellitus—Dexamethasone—ankylosing spondylitis	0.000561	0.00987	CcSEcCtD
Canagliflozin—Pancreatitis—Prednisolone—ankylosing spondylitis	0.000496	0.00872	CcSEcCtD
Canagliflozin—Diabetes mellitus—Prednisone—ankylosing spondylitis	0.000489	0.0086	CcSEcCtD
Canagliflozin—Breast disorder—Methylprednisolone—ankylosing spondylitis	0.000485	0.00853	CcSEcCtD
Canagliflozin—Cystitis noninfective—Methotrexate—ankylosing spondylitis	0.000478	0.00841	CcSEcCtD
Canagliflozin—Cystitis—Methotrexate—ankylosing spondylitis	0.000473	0.00831	CcSEcCtD
Canagliflozin—Vaginal infection—Methotrexate—ankylosing spondylitis	0.000462	0.00813	CcSEcCtD
Canagliflozin—Pancreatitis—Triamcinolone—ankylosing spondylitis	0.000456	0.00802	CcSEcCtD
Canagliflozin—Pancreatitis—Methylprednisolone—ankylosing spondylitis	0.000455	0.008	CcSEcCtD
Canagliflozin—Bladder pain—Methotrexate—ankylosing spondylitis	0.000443	0.00778	CcSEcCtD
Canagliflozin—Urine output increased—Methotrexate—ankylosing spondylitis	0.000443	0.00778	CcSEcCtD
Canagliflozin—Diabetes mellitus—Methotrexate—ankylosing spondylitis	0.000409	0.00718	CcSEcCtD
Canagliflozin—Polyuria—Methotrexate—ankylosing spondylitis	0.000405	0.00712	CcSEcCtD
Canagliflozin—Photosensitivity—Methotrexate—ankylosing spondylitis	0.000405	0.00712	CcSEcCtD
Canagliflozin—Renal failure acute—Methotrexate—ankylosing spondylitis	0.000385	0.00677	CcSEcCtD
Canagliflozin—Pancreatitis—Prednisone—ankylosing spondylitis	0.00036	0.00634	CcSEcCtD
Canagliflozin—Erythema—Prednisolone—ankylosing spondylitis	0.000352	0.0062	CcSEcCtD
Canagliflozin—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.000337	0.00593	CcSEcCtD
Canagliflozin—Erythema—Triamcinolone—ankylosing spondylitis	0.000324	0.0057	CcSEcCtD
Canagliflozin—Erythema—Methylprednisolone—ankylosing spondylitis	0.000323	0.00569	CcSEcCtD
Canagliflozin—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.000323	0.00569	CcSEcCtD
Canagliflozin—Angioedema—Prednisolone—ankylosing spondylitis	0.000322	0.00566	CcSEcCtD
Canagliflozin—Breast disorder—Methotrexate—ankylosing spondylitis	0.000321	0.00565	CcSEcCtD
Canagliflozin—Syncope—Prednisolone—ankylosing spondylitis	0.000316	0.00556	CcSEcCtD
Canagliflozin—Loss of consciousness—Prednisolone—ankylosing spondylitis	0.00031	0.00545	CcSEcCtD
Canagliflozin—Angiopathy—Dexamethasone—ankylosing spondylitis	0.000306	0.00539	CcSEcCtD
Canagliflozin—Angiopathy—Betamethasone—ankylosing spondylitis	0.000306	0.00539	CcSEcCtD
Canagliflozin—Convulsion—Prednisolone—ankylosing spondylitis	0.000305	0.00537	CcSEcCtD
Canagliflozin—Pancreatitis—Methotrexate—ankylosing spondylitis	0.000301	0.00529	CcSEcCtD
Canagliflozin—Angioedema—Triamcinolone—ankylosing spondylitis	0.000296	0.00521	CcSEcCtD
Canagliflozin—Angioedema—Methylprednisolone—ankylosing spondylitis	0.000295	0.0052	CcSEcCtD
Canagliflozin—Erythema—Betamethasone—ankylosing spondylitis	0.000294	0.00517	CcSEcCtD
Canagliflozin—Erythema—Dexamethasone—ankylosing spondylitis	0.000294	0.00517	CcSEcCtD
Canagliflozin—Syncope—Triamcinolone—ankylosing spondylitis	0.000291	0.00511	CcSEcCtD
Canagliflozin—Syncope—Methylprednisolone—ankylosing spondylitis	0.00029	0.0051	CcSEcCtD
Canagliflozin—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.000285	0.00501	CcSEcCtD
Canagliflozin—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.000284	0.005	CcSEcCtD
Canagliflozin—Shock—Prednisolone—ankylosing spondylitis	0.000283	0.00498	CcSEcCtD
Canagliflozin—Convulsion—Triamcinolone—ankylosing spondylitis	0.000281	0.00494	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Methotrexate—ankylosing spondylitis	0.00028	0.00493	CcSEcCtD
Canagliflozin—Convulsion—Methylprednisolone—ankylosing spondylitis	0.00028	0.00493	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000273	0.00481	CcSEcCtD
Canagliflozin—Dry mouth—Triamcinolone—ankylosing spondylitis	0.00027	0.00474	CcSEcCtD
Canagliflozin—Angioedema—Dexamethasone—ankylosing spondylitis	0.000269	0.00472	CcSEcCtD
Canagliflozin—Angioedema—Betamethasone—ankylosing spondylitis	0.000269	0.00472	CcSEcCtD
Canagliflozin—Angiopathy—Prednisone—ankylosing spondylitis	0.000267	0.00469	CcSEcCtD
Canagliflozin—Syncope—Dexamethasone—ankylosing spondylitis	0.000264	0.00464	CcSEcCtD
Canagliflozin—Syncope—Betamethasone—ankylosing spondylitis	0.000264	0.00464	CcSEcCtD
Canagliflozin—Infection—Triamcinolone—ankylosing spondylitis	0.000263	0.00462	CcSEcCtD
Canagliflozin—Infection—Methylprednisolone—ankylosing spondylitis	0.000262	0.00461	CcSEcCtD
Canagliflozin—Shock—Triamcinolone—ankylosing spondylitis	0.00026	0.00458	CcSEcCtD
Canagliflozin—Shock—Methylprednisolone—ankylosing spondylitis	0.00026	0.00457	CcSEcCtD
Canagliflozin—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000259	0.00455	CcSEcCtD
Canagliflozin—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000258	0.00454	CcSEcCtD
Canagliflozin—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000258	0.00454	CcSEcCtD
Canagliflozin—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000256	0.00451	CcSEcCtD
Canagliflozin—Malnutrition—Prednisone—ankylosing spondylitis	0.000256	0.0045	CcSEcCtD
Canagliflozin—Erythema—Prednisone—ankylosing spondylitis	0.000256	0.0045	CcSEcCtD
Canagliflozin—Convulsion—Dexamethasone—ankylosing spondylitis	0.000255	0.00448	CcSEcCtD
Canagliflozin—Convulsion—Betamethasone—ankylosing spondylitis	0.000255	0.00448	CcSEcCtD
Canagliflozin—Hypotension—Methylprednisolone—ankylosing spondylitis	0.000247	0.00434	CcSEcCtD
Canagliflozin—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000243	0.00427	CcSEcCtD
Canagliflozin—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000241	0.00424	CcSEcCtD
Canagliflozin—Infection—Betamethasone—ankylosing spondylitis	0.000238	0.00419	CcSEcCtD
Canagliflozin—Infection—Dexamethasone—ankylosing spondylitis	0.000238	0.00419	CcSEcCtD
Canagliflozin—Shock—Dexamethasone—ankylosing spondylitis	0.000236	0.00415	CcSEcCtD
Canagliflozin—Shock—Betamethasone—ankylosing spondylitis	0.000236	0.00415	CcSEcCtD
Canagliflozin—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000235	0.00414	CcSEcCtD
Canagliflozin—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000235	0.00414	CcSEcCtD
Canagliflozin—Angioedema—Prednisone—ankylosing spondylitis	0.000234	0.00411	CcSEcCtD
Canagliflozin—Syncope—Prednisone—ankylosing spondylitis	0.00023	0.00404	CcSEcCtD
Canagliflozin—Urticaria—Prednisolone—ankylosing spondylitis	0.000228	0.00402	CcSEcCtD
Canagliflozin—Fatigue—Triamcinolone—ankylosing spondylitis	0.000228	0.00401	CcSEcCtD
Canagliflozin—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000228	0.004	CcSEcCtD
Canagliflozin—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000225	0.00396	CcSEcCtD
Canagliflozin—Hypotension—Dexamethasone—ankylosing spondylitis	0.000224	0.00394	CcSEcCtD
Canagliflozin—Hypotension—Betamethasone—ankylosing spondylitis	0.000224	0.00394	CcSEcCtD
Canagliflozin—Angiopathy—Methotrexate—ankylosing spondylitis	0.000223	0.00392	CcSEcCtD
Canagliflozin—Convulsion—Prednisone—ankylosing spondylitis	0.000222	0.0039	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000217	0.00381	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000216	0.00379	CcSEcCtD
Canagliflozin—Erythema—Methotrexate—ankylosing spondylitis	0.000214	0.00376	CcSEcCtD
Canagliflozin—Malnutrition—Methotrexate—ankylosing spondylitis	0.000214	0.00376	CcSEcCtD
Canagliflozin—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000212	0.00373	CcSEcCtD
Canagliflozin—Urticaria—Triamcinolone—ankylosing spondylitis	0.00021	0.00369	CcSEcCtD
Canagliflozin—Urticaria—Methylprednisolone—ankylosing spondylitis	0.00021	0.00369	CcSEcCtD
Canagliflozin—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000209	0.00367	CcSEcCtD
Canagliflozin—Infection—Prednisone—ankylosing spondylitis	0.000208	0.00365	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000207	0.00364	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000207	0.00364	CcSEcCtD
Canagliflozin—Fatigue—Dexamethasone—ankylosing spondylitis	0.000207	0.00364	CcSEcCtD
Canagliflozin—Fatigue—Betamethasone—ankylosing spondylitis	0.000207	0.00364	CcSEcCtD
Canagliflozin—Shock—Prednisone—ankylosing spondylitis	0.000206	0.00362	CcSEcCtD
Canagliflozin—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000205	0.0036	CcSEcCtD
Canagliflozin—Skin disorder—Prednisone—ankylosing spondylitis	0.000203	0.00357	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000196	0.00345	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000196	0.00345	CcSEcCtD
Canagliflozin—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000195	0.00343	CcSEcCtD
Canagliflozin—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000194	0.00342	CcSEcCtD
Canagliflozin—Urticaria—Betamethasone—ankylosing spondylitis	0.000191	0.00335	CcSEcCtD
Canagliflozin—Urticaria—Dexamethasone—ankylosing spondylitis	0.000191	0.00335	CcSEcCtD
Canagliflozin—Dizziness—Prednisolone—ankylosing spondylitis	0.00019	0.00334	CcSEcCtD
Canagliflozin—Asthenia—Triamcinolone—ankylosing spondylitis	0.00019	0.00334	CcSEcCtD
Canagliflozin—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.00019	0.00334	CcSEcCtD
Canagliflozin—Abdominal pain—Betamethasone—ankylosing spondylitis	0.00019	0.00334	CcSEcCtD
Canagliflozin—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000189	0.00333	CcSEcCtD
Canagliflozin—Pruritus—Triamcinolone—ankylosing spondylitis	0.000187	0.00329	CcSEcCtD
Canagliflozin—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000187	0.00328	CcSEcCtD
Canagliflozin—Convulsion—Methotrexate—ankylosing spondylitis	0.000185	0.00326	CcSEcCtD
Canagliflozin—Rash—Prednisolone—ankylosing spondylitis	0.000181	0.00319	CcSEcCtD
Canagliflozin—Dermatitis—Prednisolone—ankylosing spondylitis	0.000181	0.00319	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000181	0.00318	CcSEcCtD
Canagliflozin—Fatigue—Prednisone—ankylosing spondylitis	0.00018	0.00317	CcSEcCtD
Canagliflozin—Constipation—Prednisone—ankylosing spondylitis	0.000179	0.00314	CcSEcCtD
Canagliflozin—Dizziness—Triamcinolone—ankylosing spondylitis	0.000175	0.00308	CcSEcCtD
Canagliflozin—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000175	0.00307	CcSEcCtD
Canagliflozin—Infection—Methotrexate—ankylosing spondylitis	0.000174	0.00305	CcSEcCtD
Canagliflozin—Asthenia—Betamethasone—ankylosing spondylitis	0.000172	0.00303	CcSEcCtD
Canagliflozin—Asthenia—Dexamethasone—ankylosing spondylitis	0.000172	0.00303	CcSEcCtD
Canagliflozin—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000171	0.00301	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000171	0.003	CcSEcCtD
Canagliflozin—Nausea—Prednisolone—ankylosing spondylitis	0.000171	0.003	CcSEcCtD
Canagliflozin—Pruritus—Betamethasone—ankylosing spondylitis	0.00017	0.00299	CcSEcCtD
Canagliflozin—Pruritus—Dexamethasone—ankylosing spondylitis	0.00017	0.00299	CcSEcCtD
Canagliflozin—Skin disorder—Methotrexate—ankylosing spondylitis	0.00017	0.00298	CcSEcCtD
Canagliflozin—Rash—Triamcinolone—ankylosing spondylitis	0.000167	0.00293	CcSEcCtD
Canagliflozin—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000167	0.00293	CcSEcCtD
Canagliflozin—Rash—Methylprednisolone—ankylosing spondylitis	0.000166	0.00293	CcSEcCtD
Canagliflozin—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000166	0.00292	CcSEcCtD
Canagliflozin—Urticaria—Prednisone—ankylosing spondylitis	0.000166	0.00292	CcSEcCtD
Canagliflozin—Abdominal pain—Prednisone—ankylosing spondylitis	0.000165	0.00291	CcSEcCtD
Canagliflozin—Hypotension—Methotrexate—ankylosing spondylitis	0.000163	0.00287	CcSEcCtD
Canagliflozin—Dizziness—Betamethasone—ankylosing spondylitis	0.000159	0.00279	CcSEcCtD
Canagliflozin—Dizziness—Dexamethasone—ankylosing spondylitis	0.000159	0.00279	CcSEcCtD
Canagliflozin—Nausea—Triamcinolone—ankylosing spondylitis	0.000157	0.00276	CcSEcCtD
Canagliflozin—Nausea—Methylprednisolone—ankylosing spondylitis	0.000157	0.00276	CcSEcCtD
Canagliflozin—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000154	0.00271	CcSEcCtD
Canagliflozin—Rash—Betamethasone—ankylosing spondylitis	0.000151	0.00266	CcSEcCtD
Canagliflozin—Rash—Dexamethasone—ankylosing spondylitis	0.000151	0.00266	CcSEcCtD
Canagliflozin—Dermatitis—Betamethasone—ankylosing spondylitis	0.000151	0.00266	CcSEcCtD
Canagliflozin—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000151	0.00266	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000151	0.00265	CcSEcCtD
Canagliflozin—Fatigue—Methotrexate—ankylosing spondylitis	0.000151	0.00265	CcSEcCtD
Canagliflozin—Asthenia—Prednisone—ankylosing spondylitis	0.00015	0.00264	CcSEcCtD
Canagliflozin—Pruritus—Prednisone—ankylosing spondylitis	0.000148	0.0026	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000143	0.00251	CcSEcCtD
Canagliflozin—Nausea—Betamethasone—ankylosing spondylitis	0.000143	0.00251	CcSEcCtD
Canagliflozin—Nausea—Dexamethasone—ankylosing spondylitis	0.000143	0.00251	CcSEcCtD
Canagliflozin—Urticaria—Methotrexate—ankylosing spondylitis	0.000139	0.00244	CcSEcCtD
Canagliflozin—Dizziness—Prednisone—ankylosing spondylitis	0.000138	0.00243	CcSEcCtD
Canagliflozin—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000138	0.00243	CcSEcCtD
Canagliflozin—Rash—Prednisone—ankylosing spondylitis	0.000132	0.00232	CcSEcCtD
Canagliflozin—Dermatitis—Prednisone—ankylosing spondylitis	0.000132	0.00231	CcSEcCtD
Canagliflozin—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000129	0.00226	CcSEcCtD
Canagliflozin—Asthenia—Methotrexate—ankylosing spondylitis	0.000125	0.0022	CcSEcCtD
Canagliflozin—Nausea—Prednisone—ankylosing spondylitis	0.000124	0.00218	CcSEcCtD
Canagliflozin—Pruritus—Methotrexate—ankylosing spondylitis	0.000124	0.00217	CcSEcCtD
Canagliflozin—Dizziness—Methotrexate—ankylosing spondylitis	0.000116	0.00203	CcSEcCtD
Canagliflozin—Rash—Methotrexate—ankylosing spondylitis	0.00011	0.00194	CcSEcCtD
Canagliflozin—Dermatitis—Methotrexate—ankylosing spondylitis	0.00011	0.00193	CcSEcCtD
Canagliflozin—Nausea—Methotrexate—ankylosing spondylitis	0.000104	0.00182	CcSEcCtD
